Cancer Home > Generic Kyprolis
Patents and exclusivity rights currently prevent any company from making a generic Kyprolis (carfilzomib) product. The earliest predictable date that a generic version could become available is April 2025, when the first patent is set to expire. Although carfilzomib is sometimes called the "generic name" of Kyprolis, it is simply the active ingredient in the medication and not a generic version of it.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or other patents for new Kyprolis uses. Once the patent expires, several companies may begin manufacturing a generic Kyprolis drug.
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.